FilingReader Intelligence
Fosun Pharma boosts shareholder returns despite slight revenue dip
March 27, 2025 at 11:25 PM UTC•By FilingReader AI
** Shanghai Fosun Pharmaceutical Group (SSE:600196) announced its 2024 annual results, showcasing a resilient performance amidst a complex market landscape. While revenue saw a slight dip to RMB 41.07 billion, the company is prioritizing shareholder returns by proposing a cash dividend of RMB 0.32 per share, totaling RMB 850.27 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Fosun Pharma: 2024 Annual Audit ReportMarch 25, 2025 at 01:31 PM UTC
Announcement of Fosun Pharma's 2024 Profit Distribution PlanMarch 25, 2025 at 01:31 PM UTC
Summary of Fosun Pharma's 2024 Annual ReportMarch 25, 2025 at 01:31 PM UTC
Fosun Pharma's announcement on approval of drug clinical trials for its holding subsidiaryMarch 25, 2025 at 01:31 PM UTC
Fosun Pharma: 2024 Internal Control Audit ReportMarch 25, 2025 at 01:31 PM UTC
SSE:600196•Shanghai Stock Exchange
PharmaceuticalsShanghai Blue Chip
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime